ORACLE

Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi.
  • These presentations will provide new insight on the clinical utility and real-world impact of the Nodify CDT and Nodify XL2 tests in the comprehensive management of lung nodules.
  • Dr. Kurman, remarked, "The data we're presenting at CHEST 2023 underscores the transformative potential of the Nodify XL2 test in managing all types of lung nodules.
  • However, published data shows that the performance of PET/CT imaging alone is compromised in assessing small lung nodules for cancer.

Vector Space Biosciences (SBIO) Is Now Available for Trading on LBank Exchange

Retrieved on: 
Sunday, September 24, 2023

Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023.

Key Points: 
  • Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023.
  • For all users of LBank Exchange, the SBIO/USDT trading pair is now officially available for trading.
  • Vector Space Biosciences specializes in harnessing language modeling, correlation matrix datasets, and real-time updates to uncover hidden relationships within scientific data, particularly in the realm of space biosciences.
  • Vector Space Biosciences collaborates with a diverse set of partners to facilitate new insights, hypotheses, interpretations, and discoveries in space biosciences for the benefit of humanity.

NEC Enhances Healthcare Communications with New Integrations: UNIVERGE BLUE ENGAGE Contact Center + Leading Electronic Healthcare Record Systems

Retrieved on: 
Wednesday, August 23, 2023

These integrations seamlessly connect the omni-channel UNIVERGE BLUE ENGAGE contact center solution with industry-leading electronic health record (EHR) systems, including Epic®, ORACLE Cerner® and MEDITECH®.

Key Points: 
  • These integrations seamlessly connect the omni-channel UNIVERGE BLUE ENGAGE contact center solution with industry-leading electronic health record (EHR) systems, including Epic®, ORACLE Cerner® and MEDITECH®.
  • With the evolution of remote work and virtual healthcare, NEC's UNIVERGE BLUE Healthcare Solutions practice is at the forefront of innovating cloud-based communication and collaboration solutions.
  • “The integration of UNIVERGE BLUE ENGAGE Contact Center with leading electronic health record systems exemplifies our unwavering commitment to empowering healthcare professionals and fostering seamless, secure and patient-centered interactions.
  • These integrations are available directly to customers and through NEC’s UNIVERGE BLUE Channel Partner ecosystem as an add-on service for the UNIVERGE BLUE ENGAGE contact center solution.

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Retrieved on: 
Tuesday, August 22, 2023

The data will be presented by principal investigator of the ORACLE study, Michael Pritchett, DO, MPH, on Thursday, Aug. 24, 2023 in a live poster presentation in Chicago, IL.

Key Points: 
  • The data will be presented by principal investigator of the ORACLE study, Michael Pritchett, DO, MPH, on Thursday, Aug. 24, 2023 in a live poster presentation in Chicago, IL.
  • The Nodify XL2 test is designed to identify likely benign lung nodules that can be monitored with computed tomography (CT) scans instead of costly invasive procedures.
  • Additionally, the proportion of patients sent to CT surveillance with malignant nodules did not differ between the Nodify XL2 group and the control group.
  • “It is very encouraging that the Nodify XL2 test is helping physicians avoid unnecessary invasive procedures on benign lung nodules and prioritize patients with a higher risk of lung cancer.

Biodesix Announces Second Quarter 2023 Results and Highlights

Retrieved on: 
Monday, August 7, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update
    “I am very pleased to announce another record-setting quarter from our core lung diagnostics,” said Scott Hutton, President and Chief Executive Officer.
  • All board members, all Section 16 officers, and additional members of the Biodesix leadership team participated in the round raising $27.5 million in equity funding to further support our growth.
  • We also maintained strong cost discipline, with sustainable and improving gross margins to 73% from 65%, and reducing our Operating Expense excluding direct costs and expenses by $2.7 million, all versus first quarter 2023.
  • The Company reaffirms our 2023 financial outlook and expects to generate between $52 million and $55 million in total revenue in 2023.

Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Retrieved on: 
Wednesday, July 12, 2023

Lung nodules are a common clinical finding with the increased use of medical imaging for general diagnostic purposes and the expansion of lung cancer screening eligibility.

Key Points: 
  • Lung nodules are a common clinical finding with the increased use of medical imaging for general diagnostic purposes and the expansion of lung cancer screening eligibility.
  • Lung nodules represent an opportunity for early detection of lung cancer but pose a diagnostic dilemma because up to 95% of lung nodules are benign.
  • In ORACLE, the prospective, real-world clinical utility study, patients with benign nodules managed with the Nodify XL2 test were 74% less likely to undergo an unnecessary invasive procedure compared to the control group.
  • “Clinical utility is an important step to demonstrate that the test is informing diagnostic decision making in a clinical setting.

Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

Retrieved on: 
Thursday, May 18, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.
  • The meeting will take place May 19-24, 2023, in Washington, DC.
  • Data from the abstract titled, Assessment of an Integrated Classifier’s Ability to Distinguish Benign from Malignant Nodules: Subgroup Analysis of the ORACLE Registry, presented by Dr. K. J.
  • Both poster presentations will occur during ATS discussion Session C99 – Advances in Biomarkers Across the Lung Cancer Continuum.

Guidehouse Insights Names Oracle a Leader in Advanced Distribution Management Systems

Retrieved on: 
Monday, March 13, 2023

SAN DIEGO, March 13, 2023 /PRNewswire/ -- ORACLE ENERGY AND WATER EDGE -- As distributed energy resources (DERs) surge, distribution utilities need new tools to modernize the grid and safely integrate and manage the influx of new energy sources and devices. Recognizing Oracle's ability to deliver the holistic enterprise-wide platform and data intelligence utilities need to navigate this transition, Guidehouse Insights again named Oracle Energy and Water a leader in its ADMS Vendors report.1 See the results here.

Key Points: 
  • The Guidehouse Insights Leaderboard for Advanced Distribution Management System (ADMS) Vendors scored eight companies on their strategy and execution based on 10 criteria.
  • "The Guidehouse Insights report clearly shows that Oracle Utilities NMS continues moving up the Leaderboard by fueling grid evolution at scale.
  • Oracle was also named #1 in Guidehouse Insights reports - AI Vendors for Distributed Energy Resource Integration, Home Energy Management, and Smart Meter Analytics.
  • Guidehouse Insights, "Guidehouse Insights Leaderboard: ADMS Vendors," Michael Kelly and Roberto Rodriguez Labastida, Q1 2023.

Wemade Unveils the 1st DAO Lineup on NILE

Retrieved on: 
Friday, February 24, 2023

SINGAPORE, Feb. 24, 2023 /PRNewswire/ -- NILE (NFT Is Life Evolution), a DAO & NFT platform based on the WEMIX3.0 mainnet, has unveiled its first DAO lineup: WONDER DAO, ARTEUM DAO, DELTA DAO, and ORACLE DAO.

Key Points: 
  • SINGAPORE, Feb. 24, 2023 /PRNewswire/ -- NILE (NFT Is Life Evolution), a DAO & NFT platform based on the WEMIX3.0 mainnet, has unveiled its first DAO lineup: WONDER DAO, ARTEUM DAO, DELTA DAO, and ORACLE DAO.
  • Each DAO has its own community that works together to achieve common goals, like the WONDER DAO mission to grow the ecosystem.
  • WONDER DAO, WONDER 1 of 40 WONDERS, or node council partners of the mainnet WEMIX3.0, has been formed to contribute to the growth and advance of the WEMIX ecosystem.
  • In addition, NILE is currently developing DELTA DAO, a WEMIX3.0-based automatic asset management protocol which users can use to easily access and utilize DeFi services.

Wemade Unveils the 1st DAO Lineup on NILE

Retrieved on: 
Friday, February 24, 2023

SINGAPORE, Feb. 24, 2023 /PRNewswire/ -- NILE (NFT Is Life Evolution), a DAO & NFT platform based on the WEMIX3.0 mainnet, has unveiled its first DAO lineup: WONDER DAO, ARTEUM DAO, DELTA DAO, and ORACLE DAO.

Key Points: 
  • SINGAPORE, Feb. 24, 2023 /PRNewswire/ -- NILE (NFT Is Life Evolution), a DAO & NFT platform based on the WEMIX3.0 mainnet, has unveiled its first DAO lineup: WONDER DAO, ARTEUM DAO, DELTA DAO, and ORACLE DAO.
  • Each DAO has its own community that works together to achieve common goals, like the WONDER DAO mission to grow the ecosystem.
  • WONDER DAO, WONDER 1 of 40 WONDERS, or node council partners of the mainnet WEMIX3.0, has been formed to contribute to the growth and advance of the WEMIX ecosystem.
  • In addition, NILE is currently developing DELTA DAO, a WEMIX3.0-based automatic asset management protocol which users can use to easily access and utilize DeFi services.